Watson, Barr settle patent dispute

CORONA, Calif. Watson Pharmaceuticals has settled a lawsuit against Teva subsidiary Barr Labs over Barr’s attempt to market a version of a Watson overactive bladder drug, Watson announced Wednesday.

The lawsuit concerned Watson’s drug Oxytrol (oxybutnynin) transdermal patches. Barr had submitted an approval application with the Food and Drug Administration to market a generic version.

Under the terms of the settlement, Watson has given Barr a license to begin marketing its version of Oxytrol in April 2015 or possibly earlier in exchange for royalties on sales.